- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Cubist Pharmaceuticals Inc
+ Add to WatchlistCBST:US
55.4900 USD 0.5400 0.96%As of 16:30:00 ET on 05/24/2013.
Snapshot for Cubist Pharmaceuticals Inc (CBST)
| Open: | 54.8900 | Day's Range: | 54.1600 - 55.6400 | Volume: | 633,786 |
|---|---|---|---|---|---|
| Previous Close: | 56.0300 | 52wk Range: | 36.7300 - 56.5400 | 1-Yr Rtn: | +39.04% |
Key Statistics for CBST
| Current P/E Ratio (ttm) | 27.5049 |
|---|---|
| Estimated P/E(12/2013) | 30.1301 |
| Relative P/E vs. SPX | 1.7051 |
| Earnings Per Share (USD) (ttm) | 2.0200 |
| Est. EPS (USD) (12/2013) | 1.8440 |
| Est. PEG Ratio | 1.1588 |
| Market Cap (M USD) | 3,622.86 |
| Shares Outstanding (M) | 65.21 |
| 30 Day Average Volume | 991,642 |
| Price/Book (mrq) | 3.5633 |
| Price/Sale (ttm) | 3.7740 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/19/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CBST
Company Profile & Key Executives for CBST
Cubist Pharmaceuticals, Inc. is a drug company that discovers, develops, and commercializes novel drugs to treat infections. The Company's lead product is a unique agent with bactericidal activity that addresses the critical need for new antibiotics with potent activity against life threatening infections.
| Michael Weston Bonney "Mike"Chief Executive Officer | Robert J Perez "Rob"President/COO |
| Steven C Gilman "Steve"Exec VP:Research & Development | Michael Tomsicek "Mike"Senior VP/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CBST News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page